Business
NuLife Announces Second Round of Pre-Clinical Surgeries
NuLife Announces Second Round of Pre-Clinical Surgeries.
About this update from Gulf West Security Network Inc.
[{"type":"text","content":"\nNuLife Announces Second Round of Pre-Clinical Surgeries\n\nNuLife Announces Second Round of Pre-Clinical Surgeries\n\n\nRefining the Revolutionary Approach to Kidney Transplant\n\nSAN CLEMENTE, CA--(Marketwired - August 29, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife BioMed, Inc., today announced it is initiating the second round of pre-clinical surgeries to refine the NuLife Technique, a means to potentially eliminate the need for organ or tissue matching between donor and recipient in organ transplants and the necessity for anti-rejection drugs after surgery.The series of surgeries build upon each other, and are part of the pre-clinical trial of the NuLife Technique, which commenced on August 8th at Florida International University, to evaluate the NuLife process and prove that the NuLife Technique is viable and effective.This surgery, which is being conducted by Doctors Juan Arenas and Tjasa Hranjec, will serve to confirm results seen in the first surgery, as well as an opportunity to fine tune the NuLife Technique. Juan Arenas, MD, FACS, MBA, is a board-certified transplant surgeon, Director of the Solid Organ Transplant Institute, and the Chair of Solid Organ Transplant at Memorial Regional Hospital in Hollywood, Florida. Prior to this role, he served as the Chief of the Division of Surgical Transplantation at the University of Texas (UT) Southwestern Medical Center for the past 10 years. Tjasa Hranjec, MD, MS-CR is a Board certified trauma/critical care and transplant surgeon, the director of the Transplant Intensive Care Unit at the Memorial Regional Hospital in Hollywood.\"We are excited that the team was able to move into the second round as quickly as they have,\" said John Hollister, NuLife Sciences Chief Executive Officer. \"We anticipate being able to review the results from the first round in the coming two weeks and report them at an upcoming scientific meeting.\"About NuLife SciencesNuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant te...